{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T01:13:16Z","timestamp":1793841196074,"version":"4.6.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007044","name":"Sociedade Portuguesa de Nefrologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007044","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.neurol.2026.01.270","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T15:30:55Z","timestamp":1775057455000},"page":"344-351","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["NMOSD and MOGAD: Updates on diagnostic criteria"],"prefix":"10.1016","volume":"182","author":[{"given":"R.","family":"Marignier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Leal Rato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2026.01.270_bib0135","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S1474-4422(25)00270-4","article-title":"Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria","volume":"24","author":"Montalban","year":"2025","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2026.01.270_bib0140","doi-asserted-by":"crossref","first-page":"105905","DOI":"10.1016\/j.ebiom.2025.105905","article-title":"Positive cerebrospinal fluid in the 2024 McDonald criteria for multiple sclerosis","volume":"120","author":"Deisenhammer","year":"2025","journal-title":"eBioMedicine"},{"key":"10.1016\/j.neurol.2026.01.270_bib0145","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2026.01.270_bib0150","series-title":"IPND 2025 diagnostic criteria for NMOSD. Presented on 24\/09\/2025, ECTRIMS 2025, Barcelona, Spain","author":"Wingerchuk","year":"2025"},{"key":"10.1016\/j.neurol.2026.01.270_bib0155","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2026.01.270_bib0160","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/acn3.52310","article-title":"Real-world clinical experience with serum MOG and AQP4 antibody testing by live versus fixed cell-based assay","volume":"12","author":"Said","year":"2025","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.neurol.2026.01.270_bib0165","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1212\/WNL.0b013e318248dec1","article-title":"Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays","volume":"78","author":"Waters","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2026.01.270_bib0170","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.3389\/fneur.2019.01028","article-title":"AQP4 antibody assay sensitivity comparison in the era of the 2015 diagnostic criteria for NMOSD","volume":"10","author":"Prain","year":"2019","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurol.2026.01.270_bib0175","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1007\/s00415-023-11634-0","article-title":"Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD)\u00a0\u2013\u00a0revised recommendations of the Neuromyelitis Optica Stdy Group (NEMOS). Part I: diagnosis and differential diagnosis","volume":"270","author":"Jarius","year":"2023","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2026.01.270_bib0180","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jamaneurol.2023.2974","article-title":"Rapid immunodot AQP4 assay for neuromyelitis optica spectrum disorder","volume":"80","author":"Fu","year":"2023","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2026.01.270_bib0185","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1212\/NXI.0000000000000231","article-title":"Clinical utility of testing AQP4-IgG in CSF: guidance for physicians","volume":"3","author":"Majed","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.neurol.2026.01.270_bib0190","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1177\/13524585231199819","article-title":"Double-negative neuromyelitis optica spectrum disorder","volume":"29","author":"Wu","year":"2023","journal-title":"Mult Scler J"},{"key":"10.1016\/j.neurol.2026.01.270_bib0195","doi-asserted-by":"crossref","first-page":"e213537","DOI":"10.1212\/WNL.0000000000213537","article-title":"Diagnosis and management of children with atypical neuroinflammation","volume":"104","author":"Saucier","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2026.01.270_bib0200","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1001\/jamaneurol.2022.2141","article-title":"Adult-onset genetic central nervous system disorders masquerading as acquired neuroinflammatory disorders: a review","volume":"79","author":"Ayrignac","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2026.01.270_bib0205","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/WCO.0000000000001265","article-title":"Clinical characteristics of patients with myelin oligodendrocyte glycoprotein antibodies","volume":"37","author":"Maillart","year":"2024","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.neurol.2026.01.270_bib0210","doi-asserted-by":"crossref","first-page":"e200456","DOI":"10.1212\/NXI.0000000000200456","article-title":"Real-life evaluation of the MOGAD diagnostic criteria: application challenges and discrepancies","volume":"12","author":"Carta","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.neurol.2026.01.270_bib0215","doi-asserted-by":"crossref","first-page":"e200400","DOI":"10.1212\/NXI.0000000000200400","article-title":"Clinical features of children with MOG-IgG who fulfill criteria of multiple sclerosis and overlapping disorders","volume":"12","author":"Fonseca","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.neurol.2026.01.270_bib0220","doi-asserted-by":"crossref","first-page":"e200503","DOI":"10.1212\/NXI.0000000000200503","article-title":"Applying the supporting features for MOGAD diagnosis to patients with multiple sclerosis","volume":"12","author":"Zara","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.neurol.2026.01.270_bib0225","doi-asserted-by":"crossref","DOI":"10.1038\/s41582-024-01005-2","article-title":"The influence of MOGAD on diagnosis of multiple sclerosis using MRI","author":"Geraldes","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.neurol.2026.01.270_bib0230","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acn3.70080","article-title":"Brain characteristics in patients with myelin oligodendrocyte glycoprotein antibody-associated disorder by 7.0 Tesla MRI","volume":"12","author":"Su","year":"2025","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.neurol.2026.01.270_bib0235","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1212\/WNL.0000000000201465","article-title":"Differentiating multiple sclerosis from AQP4-neuromyelitis optica spectrum disorder and MOG-antibody disease with imaging","volume":"100","author":"Cortese","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2026.01.270_bib0240","doi-asserted-by":"crossref","first-page":"105406","DOI":"10.1016\/j.msard.2023.105406","article-title":"Susceptibility-weighted image features in AQP4-negative-NMOSD versus MS","volume":"82","author":"Gao","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurol.2026.01.270_bib0245","doi-asserted-by":"crossref","first-page":"e200386","DOI":"10.1212\/NXI.0000000000200386","article-title":"Diagnostic utility of Kappa free light chain index in adults with inaugural optic neuritis","volume":"12","author":"Demortiere","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.neurol.2026.01.270_bib0250","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1111\/ene.15897","article-title":"Relevance of kappa free light chains index in patients with aquaporin-4 or myelin-oligodendrocyte-glycoprotein antibodies","volume":"30","author":"Deschamps","year":"2023","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.neurol.2026.01.270_bib0255","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2025-335953","article-title":"KFLC-index distinguishes multiple sclerosis from anti-myelin oligodendrocyte glycoprotein and aquaporin 4 diseases in a Chinese cohort","author":"Tan","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2026.01.270_bib0260","doi-asserted-by":"crossref","first-page":"e200347","DOI":"10.1212\/NXI.0000000000200347","article-title":"Neurofilament light chain as a discriminator of disease activity status in MOG antibody-associated disease","volume":"12","author":"Gomes ABAGR","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflammation"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378726004601?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378726004601?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:14:04Z","timestamp":1792674844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378726004601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0035378726004601"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2026.01.270","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NMOSD and MOGAD: Updates on diagnostic criteria","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2026.01.270","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}